A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep
Open Access
- 1 January 2019
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 9 (16), 4608-4623
- https://doi.org/10.7150/thno.35188
Abstract
Over 20% of cancer 'driver' genes encode chromatin regulators. Long noncoding RNAs (lincRNAs), which are dysregulated in various cancers, play a critical role in chromatin dynamics and gene regulation by interacting with key epigenetic regulators. It has been previously reported that the lincRNA HOTAIR mediates recruitment of polycomb repressive complex 2 (PRC2) leading to aberrant transcriptional silencing of tumor suppressor genes in glioma and breast cancer. Thus, lincRNA HOTAIR can serve as a promising therapeutic target. Herein, we identified a small-molecule compound AC1Q3QWB (AQB) as a selective and efficient disruptor of HOTAIR-EZH2 interaction, resulting in blocking of PRC2 recruitment and increasing tumor suppressors expression. Methods: Molecular docking and high-throughput screening were performed to identify the small compound, AQB. RIP and ChIRP assays were carried to assess the selective interference of AQB with the HOTAIR-EZH2 interaction. The effects of AQB on tumor malignancy were evaluated in a variety of cancer cell lines and orthotopic breast cancer models. The combination therapy of AQB and 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2 was used in vitro and in orthotopic breast cancer and glioblastoma patient-derived xenograft (PDX) models. Results: Tumor cells highly expressing HOTAIR and EZH2 were sensitive to AQB. APC2, as one of the target genes, was significantly up-regulated by AQB and led to degradation of beta-catenin resulting in suppression of Wnt/beta-catenin signaling which may contribute to inhibition of tumor growth and metastasis in vitro and in orthotopic breast cancer models. Remarkably, AQB enhanced the toxicity of DZNep in vitro. In orthotopic breast cancer and glioblastoma patient-derived xenografts (PDX) models, the combination of low doses of AQB and DZNep realized much better killing than DZNep treatment alone. Conclusion: AQB is a HOTAIR-EZH2 inhibitor, which blocks PRC2 recruitment and has great potential as an effective agent for targeted cancer therapy.Keywords
This publication has 45 references indexed in Scilit:
- Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cellsBlood, 2009
- DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylationMolecular Cancer Therapeutics, 2009
- Biochemical mechanisms of gene regulation by polycomb group protein complexesCurrent Opinion in Genetics & Development, 2009
- Kcnq1ot1 Antisense Noncoding RNA Mediates Lineage-Specific Transcriptional Silencing through Chromatin-Level RegulationMolecular Cell, 2008
- Functional Demarcation of Active and Silent Chromatin Domains in Human HOX Loci by Noncoding RNAsCell, 2007
- Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cellsGenes & Development, 2007
- EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsProceedings of the National Academy of Sciences of the United States of America, 2003
- Cancer Epigenetics: Dna Methylation and Chromatin Alterations in Human CancerAdvances in experimental medicine and biology, 2003
- The polycomb group protein EZH2 is involved in progression of prostate cancerNature, 2002
- Identification of APC2, a homologue of the adenomatous polyposis coli tumour suppressorCurrent Biology, 1999